Galderma launches clinical trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin

Ella Day | June 27, 2025 | News story | Research and Development |  Dermatology, Galderma, chronic pruritus of unknown origin, clinical trials, dermatological conditions, dermatology, nemolizumab, systemic sclerosis 

Galderma has announced the launch of two phase 2 clinical trials evaluating its monoclonal antibody, nemolizumab, in two conditions: systemic sclerosis (SSc) and chronic pruritus of unknown origin (CPUO). The trials mark an expansion of nemolizumab’s potential therapeutic applications beyond its existing approvals for prurigo nodularis and moderate-to-severe atopic dermatitis.

Nemolizumab targets the IL-31 receptor alpha, blocking IL-31 signalling – a neuroimmune cytokine implicated in driving inflammation, fibrosis and chronic itch. Both SSc and CPUO involve symptoms directly associated with these mechanisms, suggesting nemolizumab could offer much-needed relief where treatment options remain limited.

The SSc trial will assess the safety and efficacy of nemolizumab in patients with the rare autoimmune condition, which causes widespread fibrosis of the skin and internal organs. With no current therapies addressing the disease systemically, this study represents a significant step in advancing care for patients with this life-threatening condition.

Meanwhile, the CPUO study will explore nemolizumab’s ability to alleviate severe and persistent itch in patients where no clear cause is identifiable – a condition often likened to chronic pain. This trial will investigate whether IL-31 inhibition can offer relief where current therapies fall short.

Both trials are expected to begin enrollment in the second half of 2025, reinforcing Galderma’s commitment to addressing underserved dermatological conditions with high unmet need.

Ella Day
27/6/25